Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | PharmaVentures Reports

Trends in Pharmaceutical Deal Making: An Analysis of Valuations, Deal Structures and Deal Types
This report is a must-have report for all involved in business development, marketing or competitive intelligence in understanding what lies behind such deals and how they come about.

In deal making, it can be hard to pick the optimum deal type for your situation. Even the most accomplished deal maker is unlikely to have been involved in each and every type of deal.

This indispensable report answers numerous key questions including:

•What is the rationale for different deal structures?

•What is the most relevant deal type to use in a particular situation?

•What are the key issues that must be considered for each deal type?

•How do I value these deals?

•What do these deals look like in real life?

•What is the impact of the economic downturn on deals?

PharmaDeals Review
FAST. EXPERT. RELIABLE

Online publication from the international experts in Deals and Alliances

PharmaDeals Review® offers incisive deal intelligence

Our research shows that whether you are in a large or a small company, keeping up to date with industry intelligence is vital, but your time is at a premium. You need to understand the implications of the latest industry deals, and you need to know fast. You need a format which is focused and instantly digestible and accessible. But at the same time you want access to a wealth of data and analyses tools for deeper insight.

Guide to Valuation of Pharmaceutical Licensing Deals
Building on an established reputation in the area of deal negotiation and valuation, PharmaVentures is pleased to announce the release of their revised, best-selling Industry Standard Report.

This important Report takes into account all recent developments and focuses on the issues of most concern to business development and licensing professionals within the large pharmaceutical, biotechnology and academic network. It fully addresses financial modelling and provides detailed valuation examples. Its content has been formulated and thoroughly tested.

Pharmaceutical Deal Types - The Essential Guide for Deal Makers
This report is a must-have report for all involved in business development, marketing or competitive intelligence in understanding what lies behind such deals and how they come about.

In deal making, it can be hard to pick the optimum deal type for your situation. Even the most accomplished deal maker is unlikely to have been involved in each and every type of deal.

This indispensable report answers numerous key questions including:

* What is the rationale for different deal structures?

* What is the most relevant deal type to use in a particular situation?

* What are the key issues that must be considered for each deal type?

* How do I value these deals?

* What do these deals look like in real life?

* What is the impact of the economic downturn on deals?

The report analyses each type of deal in detail and, in addition, is supported by extensive analysis and case studies of real life examples from PharmaDeals® v2 Agreements and PharmaDeals Review.

Effective Deal Making in Drug Delivery
"Looming patent expiry a major force in driving valuation"

Drugs with annual sales totalling over US$86 B in 2007 are due to go off patent by 2012. Therefore, the application of novel drug delivery technologies to such existing therapeutics is an attractive means of prolonging the commerical viability of marketed drugs.

The Royalty Rate Report 2009: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector
The Definitive Industry Reference, this report is a “must read” for anyone involved in deal making who wants to get the maximum value from their next deal.

"The report sets out to give the reader a full insight into determining valuation and royalties and the huge impact that these terms can have on deals and their ultimate survival." Dr Fintan Walton, CEO of PharmaVentures

The content has been formulated by leveraging over 15 years of experience in assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making, and in response to valued feedback from our extensive market research. This report follows on from the publication of previous top selling reports on the topic of royalty rates.

Competition Law and Intellectual Property Strategy in the Pharmaceuticals Sector
This report provides an overview of the key issues of intellectual property strategy and competition law strategy affecting pharmaceuticals suppliers. Written by Bird & Bird, it sets out the essential issues concerning the intellectual property regime and the application of competition law in the pharmaceuticals sector, and the sector-specific regulatory provisions affecting competition.

Pricing and Reimbursement Risk and Opportunity in Pharmaceutical Deal Making
This covers those essential market changing initiatives which make tomorrow’s drug market different from today’s. Successful deal making has accurate valuation at its heart. Anything that impacts a drugs ability to achieve in the future a fair and profitable market price impacts its value today. The current market is more challenging than ever before. Payer-driven price negotiation for reimbursement, and cost-containment programmes to control prescribing, both challenge the traditional pricing model the industry has used to generate valuable R&D resource to further the search for innovation and better disease control.

Valuing and Structuring Pharmaceutical Licensing Agreements
This publication provides an essential grounding in how to use accepted and reliable methods for valuing pharmaceutical and biotech projects. Whether you are about to negotiate a licensing deal or need to perform a rigorous portfolio review, it is vital that you understand both the value of a project today and how that value can be built over time. The methods presented here provide answers to both questions through the combination of historical analysis of what the market has been willing to pay for similar products and technologies, and forward looking projections that explicitly handle the issues of risk, time, cost and reward. Potential elements of deals are also discussed, as are the appropriate levels of risk and reward sharing, and the significance of individual company needs and preferences. When incorporated into the valuation models that have been built, these elements will permit the development of deal structures that are attractive to both sides.

Nanotechnology-Based Drug Delivery Systems in Japan
Nanotechnology in Japan is a rapidly growing area with the Japanese government being one of the biggest financial contributors in the world (€691 million FY2004). This specialist report provides in depth information relating to the developments that are occurring within this specialist field.

Strategies and Tactics for Successful Partnering
Focusing on partnering in the healthcare industry, this new report provides a practical 'hands on' guide. The report covers key issues ranging from finding a partner and being the partner of choice, through valuation and negotiation to termination of partnerships. Complete with industry anecdotes the report examines:

> What partnering is

> How to find the right partner

> The intricacies of the partnering process

> The approach strategy

> Successfully managing the alliance

> What happens when it all goes wrong

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions